PF 5006739 - CAS 1293395-67-1
Category: Inhibitor
Please be kindly noted products are not for therapeutic use. We do not sell to patients.
Molecular Formula:
C22H22FN7O
Molecular Weight:
419.46
COA:
Inquire
Targets:
CK1
Description:
PF 5006739 is a potent inhibitor of casein kinases 1 delta (CK1δ) and 1 epsilon (CK1ε) (IC50 values are 3.9 and 17 nM, respectively). It mediates circadian rhythm phase-delaying effects in vivo.
Purity:
≥98% by HPLC
Appearance:
White solid
Synonyms:
4-[4-(4-Fluorophenyl)-1-[1-(3-isoxazolylmethyl)-4-piperidinyl]-1H-imidazol-5-yl]-2-Pyrimidinamine; 4-{4-(4-Fluorophenyl)-1-[1-(1,2-oxazol-3-ylmethyl)piperidin-4-yl]-1H-imidazol-5-yl}pyrimidin-2-amine
Storage:
Store in a cool and dry place (or refer to the Certificate of Analysis).
MSDS:
Inquire
InChIKey:
XPWHRQHBPRSUAW-UHFFFAOYSA-N
InChI:
InChI=1S/C22H22FN7O/c23-16-3-1-15(2-4-16)20-21(19-5-9-25-22(24)27-19)30(14-26-20)18-6-10-29(11-7-18)13-17-8-12-31-28-17/h1-5,8-9,12,14,18H,6-7,10-11,13H2,(H2,24,25,27)
Canonical SMILES:
C1CN(CCC1N2C=NC(=C2C3=NC(=NC=C3)N)C4=CC=C(C=C4)F)CC5=NOC=C5
1.Casein kinase 1δ/ε inhibitor PF-5006739 attenuates opioid drug-seeking behavior.
Wager TT;Chandrasekaran RY;Bradley J;Rubitski D;Berke H;Mente S;Butler T;Doran A;Chang C;Fisher K;Knafels J;Liu S;Ohren J;Marconi M;DeMarco G;Sneed B;Walton K;Horton D;Rosado A;Mead A ACS Chem Neurosci. 2014 Dec 17;5(12):1253-65. doi: 10.1021/cn500201x. Epub 2014 Oct 28.
Casein kinase 1 delta (CK1δ) and casein kinase 1 epsilon (CK1ε) inhibitors are potential therapeutic agents for a range of psychiatric disorders. The feasibility of developing a CNS kinase inhibitor has been limited by an inability to identify safe brain-penetrant compounds with high kinome selectivity. Guided by structure-based drug design, potent and selective CK1δ/ε inhibitors have now been identified that address this gap, through the design and synthesis of novel 4-[4-(4-fluorophenyl)-1-(piperidin-4-yl)-1H-imidazol-5-yl]pyrimidin-2-amine derivatives. PF-5006739 (6) possesses a desirable profile, with low nanomolar in vitro potency for CK1δ/ε (IC50 = 3.9 and 17.0 nM, respectively) and high kinome selectivity. In vivo, 6 demonstrated robust centrally mediated circadian rhythm phase-delaying effects in both nocturnal and diurnal animal models. Further, 6 dose-dependently attenuated opioid drug-seeking behavior in a rodent operant reinstatement model in animals trained to self-administer fentanyl. Collectively, our data supports further development of 6 as a promising candidate to test the hypothesis of CK1δ/ε inhibition in treating multiple indications in the clinic.
2.Targeting of the circadian clock via CK1δ/ε to improve glucose homeostasis in obesity.
Cunningham PS;Ahern SA;Smith LC;da Silva Santos CS;Wager TT;Bechtold DA Sci Rep. 2016 Jul 21;6:29983. doi: 10.1038/srep29983.
Growing evidence indicates that disruption of our internal timing system contributes to the incidence and severity of metabolic diseases, including obesity and type 2 diabetes. This is perhaps not surprising since components of the circadian clockwork are tightly coupled to metabolic processes across the body. In the current study, we assessed the impact of obesity on the circadian system in mice at a behavioural and molecular level, and determined whether pharmacological targeting of casein kinase 1δ and ε (CK1δ/ε), key regulators of the circadian clock, can confer metabolic benefit. We demonstrate that although behavioural rhythmicity was maintained in diet-induced obesity (DIO), gene expression profiling revealed tissue-specific alteration to the phase and amplitude of the molecular clockwork. Clock function was most significantly attenuated in visceral white adipose tissue (WAT) of DIO mice, and was coincident with elevated tissue inflammation, and dysregulation of clock-coupled metabolic regulators PPARα/γ. Further, we show that daily administration of a CK1δ/ε inhibitor (PF-5006739) improved glucose tolerance in both DIO and genetic (ob/ob) models of obesity. These data further implicate circadian clock disruption in obesity and associated metabolic disturbance, and suggest that targeting of the clock represents a therapeutic avenue for the treatment of metabolic disorders.
Molecular Weight Calculator Molarity Calculator Solution Dilution Calculator

Related CK1 Products


CAS 1293395-67-1 PF 5006739

PF 5006739
(CAS: 1293395-67-1)

PF 5006739 is a potent inhibitor of casein kinases 1 delta (CK1δ) and 1 epsilon (CK1ε) (IC50 values are 3.9 and 17 nM, respectively). It mediates circadian rhyt...

CAS 1391052-28-0 PF 4800567 hydrochloride

PF 4800567 hydrochloride
(CAS: 1391052-28-0)

PF 4800567 is a casein kinase 1e (CK1e) selective inhibitor that is 22 fold selective for the CK1e isoform over CK1d (IC50= 32 and 711 nM for CK1ε and CK1δ resp...

CAS 186611-52-9 SU5607 (IC261)

SU5607 (IC261)
(CAS: 186611-52-9)

IC261, also known as SU5607, is a potent and selective CK1 inhibitor. IC261 triggers the mitotic checkpoint and induces p53-dependent postmitotic effects.

CAS 1177141-67-1 CKI 7 dihydrochloride

CKI 7 dihydrochloride
(CAS: 1177141-67-1)

The hydrochloride salt form of CKI 7, which has been found to be a CK1 inhibitor.

CAS 1454585-06-8 SR-3029

SR-3029
(CAS: 1454585-06-8)

SR-3029, a small molecule inhibitor that targets specificly CK1δ/CK1ε, was effective at reducing the growth of breast cancer in multiple mouse models without an...

CAS 639052-78-1 LH846

LH846
(CAS: 639052-78-1)

LH846 is a selective inhibitor of CK1δ, which displays no inhibitory activity at CK2. It inhibits CK1δ-dependent phosphorylation and degradation of PER1 protei...

CAS 301836-43-1 D4476

D4476
(CAS: 301836-43-1)

D4476 is a potent, selective ATP-competitive inhibitor of CK1 (casein kinase 1).

CAS 950912-80-8 PF-670462

PF-670462
(CAS: 950912-80-8)

PF-670462 is a potent and selective inhibitor of CK1ε in isolated enzyme preparations. It inhibits PER protein nuclear translocation causing phase shifts in cir...

CAS 1241675-76-2 (R)-DRF053 dihydrochloride

(R)-DRF053 dihydrochloride
(CAS: 1241675-76-2)

The hydrochloride salt form of (R)-DRF053, which is a cdk/CK1 inhibitor and could be used in studies in the cancer treatment with combinations of CDK kinase and...

Chemical Structure

CAS 1293395-67-1 PF 5006739

Quick Inquiry

Verification code

Featured Items